TCGA-C8-A138-01A-11R-A115-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 13
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.450
- INTERFERON_GAMMA_RESPONSE+0.360
- INTERFERON_ALPHA_RESPONSE+0.320
- COAGULATION+0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.230
- COMPLEMENT+0.220
- MYOGENESIS+0.220
- SPERMATOGENESIS+0.220
- IL6_JAK_STAT3_SIGNALING+0.210
- KRAS_SIGNALING_UP+0.200
Top 10 suppressed
- UNFOLDED_PROTEIN_RESPONSE-0.440
- PROTEIN_SECRETION-0.420
- MITOTIC_SPINDLE-0.380
- MYC_TARGETS_V2-0.380
- ESTROGEN_RESPONSE_EARLY-0.360
- MYC_TARGETS_V1-0.360
- E2F_TARGETS-0.330
- G2M_CHECKPOINT-0.330
- MTORC1_SIGNALING-0.280
- ADIPOGENESIS-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-5L-AAT1-01A-12R-A41B-07 | — | A | 0.865 |
| 2 | 46a6f49d-2ab8-41fb-ba8c-951a160e5d08 | — | — | 0.852 |
| 3 | f426318a-9c1a-4476-a087-2b3a84096f5c | — | — | 0.846 |
| 4 | TCGA-H7-A76A-01A-51R-A34R-07 | — | — | 0.834 |
| 5 | TCGA-A2-A0CR-01A-11R-A22K-07 | — | B | 0.832 |
| 6 | TCGA-OR-A5L9-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.825 |
| 7 | TCGA-85-A513-01A-12R-A26W-07 | — | cohortA1 | 0.823 |
| 8 | SRR1458180 | GTEX | — | 0.819 |
| 9 | SRR5088828 | — | — | 0.816 |
| 10 | MNG72 | — | — | 0.813 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.020 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |